Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELISPOT-guided immunosuppression minimization in de novo kidney transplantation
2014-001325-33Phase 2Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Feb 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tacrolimus, mycophenolate mofetil and prednisolone in kidney transplant (2 arms), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Biopsy-proven acute rejection at 6 months. Started Feb 2015; status: completed.
02
Drugs
tacrolimusmycophenolate mofetilprednisolone
03
Conditions
kidney transplant
Beyond the preview
Go deeper on 2014-001325-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001325-33.